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Abstract (250 words) 
 
Purpose: Cognitive alterations are reported in breast cancer patients receiving chemotherapy. 
This has adverse effects on patients’ quality of life and function. This systematic review 
investigates the effectiveness of pharmacologic and non-pharmacologic interventions to 
manage cognitive alterations associated with breast cancer treatment. 
Methods: Medline via EBSCOhost, CINAHL and Cochrane CENTRAL were searched for 
the period January 1999 to May 2014 for prospective randomized controlled trials related to 
the management of chemotherapy-associated cognitive alterations. Included studies 
investigated the management of chemotherapy-associated cognitive alterations and used 
subjective or objective measures in patients with breast cancer during or after chemotherapy. 
Two authors independently extracted data and assessed the risk of bias. 
Results: Thirteen studies involving 1138 participants were included. Overall, the risk of bias 
for the 13 studies were either high (n=11) or unclear (n=2). Pharmacologic interventions 
included psychostimulants (n=4), epoetin alfa (n=1), and Ginkgo biloba (n=1). Non-
pharmacologic interventions were cognitive training (n=5) and physical activity (n=2). 
Pharmacologic agents were ineffective except for self-reported cognitive function in an 
epoetin alfa study. Cognitive training interventions demonstrated benefits in self-reported 
cognitive function, memory, verbal function and language and orientation/attention. Physical 
activity interventions were effective in improving executive function and self-reported 
concentration. 
Conclusion: Current evidence does not favor the pharmacologic management of cognitive 
alterations associated with breast cancer treatment. Cognitive training and physical activity 
 
 
 
Page 4 of 33 
 
interventions appear promising, but additional studies are required to establish their efficacy. 
Further research is needed to overcome methodological shortfalls such as heterogeneity in 
participant characteristics and non-standardized neuropsychological outcome measures. 
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INTRODUCTION 
Alterations in cognitive function are often observed in patients receiving chemotherapy, 
particularly those treated for breast cancer.[1] These changes can comprise poor word or 
name recall, difficulty staying focused, diminished ability to learn new things and a decreased 
ability to multitask.[2] Other alterations in executive function, information processing speed, 
language, motor function and spatial skills are documented. Depending on the nature of the 
malignancy and the treatment regimen, the time of onset, severity and duration of these 
changes are highly variable,[3] as are its affective, functional and psychosocial outcomes.[4] 
 
Depending on the type of cancer investigated, estimates of the prevalence of cancer 
treatment-related alterations in cognitive function range from 16% to 75% during 
treatment,[5] although they can endure beyond treatment. Supported by findings from 
neuropsychological tests, reports indicate that individuals can experience longer-term 
cognitive changes for as long as 21 years after chemotherapy for breast cancer.[6] In addition, 
imaging research has reported a correlation between deficits in cognitive function and white 
matter changes in the brain.[7] 
 
A number of systematic reviews and meta-analyses have investigated the prevalence of 
cognitive alteration and its association with treatment in cancer patients.[2, 8, 9] One 
systematic review[10] and one non-systematic narrative review, which discussed unpublished 
and ongoing studies,[11] focused on interventions to enhance cognitive function. Both 
reviews, however, are limited in that they included non-randomized controlled trials. 
Furthermore, Hines et al. limited their studies to cognitive behavioral therapy (CBT), which 
does not encompass the full range of interventions available.[10] In summary, a high quality, 
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comprehensive systematic review of interventions for managing chemotherapy-associated 
cognitive alterations is lacking.  
 
This clinical problem has significant adverse effects on the post-treatment quality of life and 
function of patients with cancer; hence, interventions to prevent or manage it are warranted. 
Over the next decade, the number of individuals living with a cancer diagnosis is projected to 
increase by 31%, with a high proportion being patients with breast cancer.[12] Treatment-
associated adverse effects in this growing population have significant public health 
implications if they are not well managed. In this paper, we systematically review the 
effectiveness of pharmacologic and non-pharmacologic interventions to manage alterations of 
cognitive function associated with breast cancer treatment. 
 
METHOD 
This systematic review adhered to the PRISMA statement[13] for reporting systematic 
reviews. 
 
Search strategy 
A medical librarian (JD) searched Medline via EBSCOhost, CINAHL and Cochrane 
CENTRAL for studies published between January 1999 and May 2014. The key search terms 
were chemotherapy, antineoplastic agents, chemoradiotherapy, cancer, neoplasms, 
randomized controlled trial, cognitive impairment, cognitive dysfunction, cognitive disorder, 
cognitive loss, cognitive deficit, and memory disorder. The search was limited to prospective 
randomized controlled trials (RCTs) published in English that investigated the management 
of chemotherapy-associated cognitive alterations (as primary or secondary outcomes). 
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Further manual searches of the reference lists of the relevant studies and reviews were 
undertaken by authors AC, RC and AM. 
 
Study selection 
Three authors (RC, AM and AC) pre-screened all of the search results (titles and abstracts) 
and after consensus was reached for possible inclusion, the full text of all selected papers was 
assessed. Studies were included if they were prospective RCTs; reported pharmacologic or 
non-pharmacologic interventions for cognitive alterations in breast cancer patients during or 
after chemotherapy or multimodal therapy including chemotherapy; and used subjective or 
objective measures of cognitive function. Investigations of patients with secondary brain 
metastases and studies with less than 50% of breast cancer patients in the sample or with 
patients receiving radiation monotherapy were excluded. Unpublished reports, letters to the 
editor, retrospective chart reviews, and non-RCTs were also excluded. 
 
Data extraction and rating of articles for risk of bias 
Two authors (RC, AM or AC) independently extracted the data using a pre-designed, piloted 
form. Studies were independently rated according to the Cochrane Collaboration’s risk of 
bias (ROB) criteria for a high, low or unclear ROB with respect to random sequence 
generation, allocation concealment, blinding, incomplete outcome data, selective outcome 
reporting and other sources of bias.[14] An ‘unclear’ ROB was assigned to a study if the risk 
was unclear in one or more domains, with no domain rated as a high risk. A ‘high’ ROB was 
assigned to a study if the risk was high in one or more domains. A ‘low’ ROB was assigned 
to a study rated low risk in all domains.[15] Differences in ratings were settled by discussion 
or by a third person if consensus was not achieved by the two primary reviewers. 
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Studies that compared an intervention to usual care, placebo or another intervention and that 
presented adequate data for the calculation of effect size were evaluated. To determine the 
effects of the interventions in any of the included studies, effect sizes (mean difference [MD] 
or relative risk with a 95% confidence interval [CI]) were calculated using Review Manager 
5.[14] We classified outcome assessments of <3 months, 3-6 months and ≥6 months as short-, 
medium- and long-term time points, respectively. If more than one measurement was 
reported within the defined period, the latest assessment was extracted. When published 
articles presented insufficient data to calculate the effect sizes, the authors were contacted for 
the required information. Although some studies reported statistical analyses for within-group 
changes from baseline, between-group differences were analyzed to determine the effects of 
the interventions (positive, negative or inconclusive). Data elicited from screening measures 
(e.g., Mini Mental Status Exam or High Sensitivity Cognitive Screen) were not extracted or 
analyzed. Objective outcome data were classified into the seven pre-defined domains of 
cognitive function recommended by Lezak et al.[16] and Hodgson et al.[17] 
The interventions and outcome measurements reported in these studies were heterogeneous. 
Therefore, meta-analysis was not undertaken.  
 
RESULTS 
Screening of 555 citations identified a total of 29 potentially relevant papers, the full texts of 
which were retrieved. Thirteen of the 29 studies were excluded as the majority of the 
included participants did not have breast cancer;[18-30] two studies did not include cognitive 
function measurement;[31, 32] and one study was not an RCT.[33] Thirteen studies met the 
inclusion criteria for quantitative and qualitative analyses. A flowchart detailing the 
identification of studies is provided in Figure 1. 
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Thirteen studies with a total of 1,138 participants were included in this review.[34-46] Eleven 
were undertaken in North America, one in Japan and the other in France. Six studies 
evaluated pharmacologic interventions (psychostimulants, n=4; erythropoietin stimulating 
agent, n=1, Gingko biloba, n=1). Seven studies investigated non-pharmacologic 
interventions, five of which involved cognitive training through forms of cognitive behavioral 
(n=4) or mindfulness therapy (n=1) and two of which explored physical activity. The 
characteristics of the included studies, the age of participants, treatments received, time since 
chemotherapy, sample sizes, assessment outcomes and time points for assessments are listed 
in Table 1. 
 
Ten studies provided specific information on how the random sequence was generated. One 
provided sufficient information on allocation concealment.[38] The blinding of participants, 
personnel and outcome assessments was achieved in the six pharmacologic placebo trials but 
was not possible in the seven non-pharmacologic interventions. The risk of incomplete data 
outcome reporting bias was detected in six trials,[34-37, 44, 45] which did not provide 
reasons for participant dropout, or did not undertake intention-to-treat analyses. Three 
studies[35, 37, 38] had selective outcome reporting bias, as they did not report the data on all 
outcomes measured. Overall, the ROB for the 13 studies was either high[34-40, 43-46] 
(n=11) or unclear[41, 42] (n=2) (Table 2). 
 
Pharmacologic interventions 
Psychostimulants 
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Psychostimulants including d-methylphenidate (d-MPH) (n=2), methylphenidate (n=1) and 
modafinil (n=1) were evaluated. Two studies[41, 42] evaluated the ability of d-MPH to 
enhance cognitive function. In Lower et al.’s study,[41] patients were begun on 5 mg d-MPH 
twice daily with doses titrated weekly to a maximum of 50 mg/day over 8 weeks. In the other 
d-MPH study, conducted by Mar Fan et al.,[42] patients who demonstrated compliance 
through a placebo run-in phase were randomized to d-MPH 5 mg twice daily or to matched 
placebo. Doses were titrated to a maximum of 10 mg twice daily until the end of the final 
cycle of chemotherapy. In another cross-over study,[37] breast cancer patients were 
randomized to methylphenidate 18 mg/day for 2 weeks followed by placebo for 2 weeks or 
vice versa. Modafinil was trialed in a study involving two phases.[40] In the first phase, all 
patients received modafinil 100 mg once daily for 3 days and 200 mg once daily during an 
open-label period of 4 weeks. In the subsequent phase, patients who achieved a positive 
response in terms of attention and memory in the first phase were randomized to an 
additional 4 weeks of modafinil 200 mg/day or placebo. In the assessment of short-term and 
medium-term cognitive measures between the psychostimulants and controls, there was no 
statistically significant difference in cognitive measures in any of the studies (Table 3). 
 
Epoetin alfa (EPO) 
O’Shaughnessy et al.[45] evaluated whether epoetin alfa (EPO) could enhance cognitive and 
execution function in patients with breast cancer receiving adjuvant chemotherapy. Patients 
were randomized to receive 40,000 U of EPO subcutaneously weekly or a comparable 
volume of placebo during adjuvant or neoadjuvant chemotherapy over a maximum of 12 
weeks. EPO doses were titrated according to hemoglobin levels. An improvement in self-
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perceived cognitive function (EXIT-25) was noted in patients receiving EPO compared to a 
placebo (MD=-1.60 [95% CI, -2.81 to -0.39]). 
 
Gingko biloba 
Barton et al.[34] investigated whether Ginkgo biloba could prevent cognitive impairment in 
breast cancer patients receiving adjuvant chemotherapy. Patients were randomized to receive 
Ginkgo biloba 60 mg twice daily or a placebo. The intervention commenced at the second 
cycle of chemotherapy and continued until 1 month after the completion of chemotherapy. 
The authors concluded that there were no significant differences in either subjective and 
objective cognitive measures between the two groups. 
 
Toxicities of pharmacologic interventions 
Five of the six studies[34, 37, 41, 42, 45] evaluating pharmacologic interventions reported 
adverse events associated with the interventions and the placebo. The adverse events were 
generally mild, with few Common Terminology Criteria for Adverse Events (CTCAE) Grade 
3 or 4 toxicities reported. In the two studies investigating d-MPH versus a placebo,[41, 42] 
higher incidences of dry mouth, nausea, dizziness, insomnia, anxiety and nervousness were 
reported among patients receiving d-MPH compared to the placebo. Similar findings were 
found in the methylphenidate study.[37] In the EPO study, O’Shaughnessy et al.[45] reported 
a fatal cerebrovascular accident in one patient in the EPO group. Gingko biloba was generally 
well tolerated compared to the placebo, with the exception of nausea, which was worse in the 
placebo group.[34] 
 
Non-pharmacologic interventions 
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Cognitive training 
In their three-arm study, Von Ah et al.[46] delivered memory training in one arm and speed 
processing training in the other. Memory training entailed the teaching of strategies to 
remember word lists, sequences and text material and learning how to apply the principles of 
meaningfulness, organization, visualization and association to these activities. Strategies 
focused on multiple mnemonic techniques. The intervention comprised 10 sessions, the first 
five comprising strategy instruction and practice, and the last five comprising practical 
exercises. This study reported a significant improvement in memory using objective 
neuropsychological testing compared to the control group, measured using composite scores 
for both immediate memory recall (MD=0.31, [95% CI 0.04 to 0.58]) and long term delayed 
memory (MD=0.46, [95% CI 0.12 to 0.80]). When self-perceived cognition for this 
intervention was measured with the Functional Assessment of Cancer Therapy-Cognitive 
Function (FACT-Cog), the results demonstrated a statistically significant improvement in the 
intervention group compared to the control group (MD=9.85 [95% CI, 1.67 to 18.03]). (Table 
4) The other arm of the study involved speed processing training, which aimed to 
systematically reduce stimulus duration during a series of progressively more difficult 
computerized information processing tasks. Exercises comprised time-order judgment, 
discrimination, spatial match, forward span, instruction following and narrative memory 
tasks. Although the speed processing training did not target specifically at memory 
improvement, the training yielded positive improvement in memory, measured using 
composite scores for both immediate memory recall (MD=0.43, [95% CI 0.16 to 0.70]) and 
long term delayed memory (MD=0.47, [95% CI 0.13 to 0.81]) . 
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Kesler et al.[39] targeted executive function, which in their study encompassed working 
memory, cognitive flexibility, multitasking, planning and attention. The intervention 
comprised an online computerized training program undertaken in the participants’ homes. It 
spanned 48 sessions of 20-30 minutes each over 6 weeks, with each session comprising 
combinations of 13 different exercises to enhance core executive function. Each participant 
logged in four times per week to complete five separate exercises. Exercises involved 
computerized visual stimuli that required a motor response such as a mouse click plus 
immediate feedback and reinforcement. The exercises were adaptive to individual activity, 
with the level of difficulty and complexity increasing according to a pre-determined 
algorithm. Compared to controls, the intervention participants demonstrated statistically 
significant improvements in executive function as measured by the Delis-Kaplan measure of 
verbal function and language skills (MD=2.00 [95% CI, 0.78 to 3.22]) and the Symbol 
Search measure of orientation and attention (MD=2.00 [95% CI, 0.16 to 3.84]). 
 
Dolbeault et al.[36] delivered a CBT-based stress management intervention in which 
cognition, a secondary objective, was measured with the European Organisation for Research 
and Treatment of Cancer (EORTC)-Cognitive Functioning subscale. The results were not 
statistically significant for enhancements in cognitive function. In another study, rather than 
traditional repetitive techniques of mental exercise in CBT that aim to repair damaged neuro-
circuitry to recover memory function, Ferguson et al.[38] taught strategies for cognitive 
processing and new behavior that compensated for chronic memory dysfunction. This 
intervention entailed the participants monitoring their cognitive failures and learning new 
processes to succeed in daily activities in which memory was required. The participants 
undertook twice weekly face-to-face sessions of 30-50 minutes each, with reinforcing phone 
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contacts between each visit. Differences in all outcome measures between intervention and 
control were not significant. 
 
Milbury et al.[44] delivered a Tibetan sound meditation intervention, based on the premise 
that the focused concentration of such meditation, coupled with awareness, stress reduction 
and relaxation techniques would improve objective cognitive performance. Each participant 
undertook 60-minute meditation classes twice weekly for 6 weeks. Compared to controls, the 
intervention did not result in significant differences in objectively or subjectively measured 
cognitive function. 
 
Physical activity 
One physical activity intervention[43] comprised speed feedback therapy with a bicycle 
ergometer connected to a computer. Participants pedaled the bike to match the target 
arbitrarily displayed on the computer screen, which appeared as a pathway. The participants 
were instructed to pedal while visually tracking the path, and they undertook one pedaling 
session per week for 4 weeks. The exercise load was pre-set, with the participants pedaling 
for 5 minutes each session. Compared to controls, the intervention participants had improved 
executive function and motor function as measured by the Frontal Assessment Battery 
(MD=-2.50 [95% CI, -4.56 to -0.44]). 
 
Culos-Reed et al.[35] delivered a program of modified hatha yoga, which focused on 
relaxation and awareness of breathing, body sensations and thoughts, to enhance post-
treatment quality of life. Participants progressively built flexibility, strength and balance 
while maintaining awareness and relaxation. A reduction of cognitive disorganization (as 
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measured by the Profile of Mood State [POMS] Concentration subscale) was demonstrated in 
the intervention group compared to the control immediately on conclusion of the program 
(MD=-2.50 [95% CI, -4.56 to -0.44]). 
 
DISCUSSION 
Current evidence does not favor the pharmacologic management of cognitive alteration 
associated with breast cancer treatment. The inherent variability of the psychology-derived 
cognitive training interventions makes it difficult to determine their role in practice. Some 
forms of cognitive training, particularly those that focus on quality of life enhancements, hold 
potential. For example, one study demonstrated a clinically important (i.e., subjectively 
reported) and statistically significant benefit in cognition-related quality of life.[46] Physical 
activity interventions also appear promising; however, methodological challenges in these 
studies preclude any concrete recommendations for practice. 
 
Psychostimulants effectively manage cognitive issues related to attention deficit hyperactivity 
disorder and neurodegenerative diseases. The studies included in this review hypothesized 
that these agents are as effective in treating chemotherapy-associated cognitive alterations. 
These drugs include methylphenidate and d-MPH, which are sympathomimetic amines that 
modulate neurotransmitters in the brain. They are short-acting and were prescribed for a 
limited time during chemotherapy in these studies; therefore, the long-term benefits were not 
assessed. The long-term benefits of psychostimulants have not been established,[47] which 
suggests limited clinical benefits for individuals previously treated for breast cancer.[37, 41, 
42] Similar to the sympathomimetics, modafinil improves wakefulness by acting on specific 
pathways in the brain that regulate sleep-wake patterns, without increasing the risk of the 
 
 
 
Page 16 of 33 
 
extrapyramidal side effects that are commonly observed with sympathomimetics. Although 
patients receiving this treatment achieved a level of improvement in the open-label phase of 
the study,[40] this review did not detect any subsequent benefit in the randomized phase. In 
summary, the role of these agents is limited. In addition to conventional medications, herbal 
supplements such as Ginkgo biloba were also investigated as potential cognitive 
enhancers.[34] The literature indicates that Ginkgo biloba may improve cognitive function in 
patients with mild or moderate Alzheimer’s disease or dementia.[48, 49] However, no 
benefits were observed in the study by Barton et al.[34] The authors proposed that the 
mechanisms underpinning chemotherapy-induced cognitive changes are different from those 
associated with dementia.[34] 
 
In terms of non-pharmacologic interventions, cognitive training is useful in a range of 
conditions such as traumatic brain injury, which, like chemotherapy-associated dysfunction, 
demonstrate more subtle cognitive impairment.[39] Physical activity and cognitive training 
techniques involve repeated skills and awareness practice, adaptive difficulty levels and an 
engaging and rewarding environment. It is possible that these aspects of the interventions 
might not necessarily target cognitive function. However, they could yield positive benefits in 
cognitive organization due to overall enhancement of self-reported quality of life.[38] Given 
that quality of life was a primary or secondary endpoint in six of the seven non-
pharmacologic studies in this review, and that improvements in the participants’ quality of 
life were integral to many of these interventions, this assumption is worthy of empirical 
investigation. 
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A number of other interventions not included in this review also warrant further exploration. 
For example, the effectiveness of cholinesterase inhibitors (such as donepezil) and 
antioxidants (such as vitamin E) were investigated in the prevention of cognitive decline in 
patients with small cell lung cancer.[50] Unfortunately, poor patient accrual led to the early 
closure of the study. The results of trials of granulocyte macrophage-colony stimulating 
factor,[50] memantine[19] and medical qigong[29] are also promising, and further 
evaluations are required. 
 
A number of methodological limitations featured in the included studies. First, there was at 
least one ROB in all of the studies. Second, the treatment characteristics of the participants 
were variable (e.g., they were at different stages of the disease, or received different treatment 
regimens). Third, the studies did not explain whether the participants were primed for 
cognitive impairment, with the entry criteria of many studies stipulating self-reported 
cognitive function. Fourth, the participants could not be blinded to the intervention in the 
non-pharmacologic studies. Fifth, many interventions required an intense commitment and 
repeat visits from participants, yet their sustainability over time is hard to determine, 
particularly where losses to follow-up were not documented.[34-37, 44, 45] Eleven studies 
did not evaluate the sustainability of effects beyond 3 months, by which time most of the 
interventions had ceased. Sixth, the majority of studies involved less than 50 participants per 
arm, although we recognize that many were pilot and feasibility investigations, which are 
integral components of high-quality research programs. We also recognize that there may be 
a potential risk of publication bias with studies reporting negative results remain unpublished.  
Seventh, some of the included studies did not include cognitive function as a primary 
endpoint. Trials are often not powered to detect differences in secondary outcomes. However, 
 
 
 
Page 18 of 33 
 
we included these studies due to the potential for meta-analysis. Finally, the majority of the 
studies were undertaken in North America. Given that a patient’s symptom experience is 
often culturally specific,[51] the generalizability of these results to other sociocultural 
contexts is uncertain. 
 
The problems reflected in the range of methodologies and different cognitive outcomes 
reported in these studies could be addressed through the harmonization of intervention 
studies. The International Cognition and Cancer Task Force[52] provide some useful 
guidance in this respect. They recommend for observational studies that pre-treatment 
cognitive function is assessed, that intervention and control groups are standardized in terms 
of regimen and type of cancer, and that neuropsychological outcome measures are 
harmonized. These principles are equally germane to intervention studies. 
 
This review suggests that in any intervention study in this field, the patient cohort requires 
careful consideration in terms of the stage of cancer and time since diagnosis. Studies could 
incorporate a screen for expectancy effects prior to randomization that are controlled for 
during data analysis. Expectancies and stereotypes including those associated with diagnoses 
are known to influence cognitive profiles[53]. Screening should also assess premorbid 
cognitive function if possible.[54] Subjective and objective measurements appear to be 
equally important in detecting effects. Self-reported measures detect outcomes that are 
clinically significant to patients, whereas objective neuropsychological tests remain the gold 
standard.[52] Utilization of validated tools would also be essential for future interventional 
studies. 
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Future studies would benefit from the addition of an attention control arm to address the bias 
inherent in the inability to blind in non-pharmacologic studies.[55, 56] The potential uptake 
of the intervention should also be carefully considered. Aside from feasibility studies to 
determine this, interventions need to be accessible and easy for patients to undertake. 
Technology-enhanced interventions have promise, particularly multimodal programs that 
combine physical activity and cognitive training. 
 
In summary, the burden associated with this commonly reported problem in the breast cancer 
community is significant. The science to address this problem, however, is imprecise. Well-
designed clinical studies are clearly warranted to enhance the quality of life and function of 
this growing population. 
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Figure 1. PRISMA Flow Diagram 
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Table 1. Characteristics of Included Studies (n=13) 
Study Participants Prior treatments Time since 
chemotherapy 
Comparisons Domains examined Assessed 
time point 
Barton 
(2013)[34] 
 
USA 
Breast CA: 
Both arms: 100% 
 
Age: 
I: ≥50 years: 50% 
C: ≥50 years: 
50% 
I: AC: 33%;  
AC and taxane: 52% 
Others: 15% 
Tam planned: 51%  
 
C: AC: 36%;  
AC and taxane: 52% 
Others: 12% 
Tam planned: 54%  
 
During chemo Ginkgo biloba 60 mg vs placebo twice daily 
(started at the second cycle of chemo and 
ceased at 1 month after completion of chemo) 
 
I: n=107 
C: n=103 
Orientation and attention, self-
reported cognitive function 
Short-term, 
medium-
term, 
long-term 
Culos-Reed 
(2006)[35] 
 
Canada 
Breast CA: 
Both arms: 100% 
 
Age: 
Both arms:  
51.2 (10.3) 
Both arms: 
Chemo: percentage not 
stated 
>3 months post chemo 7-week yoga program vs control  
 
I: n=10 
C: n=10  
Self-reported cognitive 
function 
Short-term 
Dolbeault 
(2009)[36] 
 
France 
Breast CA: 
Both arms: 100% 
 
Age: 
I: 54.5 (9.3) 
C: 51.6 (9.6) 
I: Chemo: 45.1% 
C: Chemo: 61.4% 
 
Not stated  A CBT-based psycho-educational group 
intervention (8 weekly 2-hour sessions) vs 
control (usual care) 
 
I: n=102 
C: n=101 
Self-reported cognitive 
function 
Short-term 
Escalante 
(2014)[37] 
 
USA 
Breast CA: 
Both arms: 100% 
 
Age: 
Both arms: 
Median 57 
(Range: 32-79) 
Both groups: 
Chemo: 100% 
Either undergoing or 
completed treatment in 
the previous 12 
months 
Methylphenidate (18 mg daily) vs placebo for 
14 days 
 
n=42 (cross-over design) 
Orientation and attention 
 
Short-term 
Ferguson 
(2012)[38] 
 
USA 
Breast CA: 
Both arms: 100% 
 
Age: 
I: 51.2 (7.3) 
C: 49.4 (5.1) 
I: Received AC/FAC 
C: Received AC/FAC 
>18 months post 
chemo 
8-week Memory and Attention Adaptive 
Training (MAAT) vs waitlist control 
 
I: n=19 
C: n=21 
Orientation and attention, 
Executive function and motor 
function, memory, self-
reported cognitive function 
Short-term  
 
Kesler (2013)[39] Breast CA: I: 100% chemo Mean (SD): 6.0 (3) Online computerized training program (5 Orientation and attention, Short-term 
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USA 
Both arms: 100% 
 
Age:  
I: 55.0 (7) 
C: 56.0 (6) 
 
70% RT 
60% HT 
 
C: 100% chemo 
63% RT  
63% HT 
months 
 
exercises 4 times weekly for 12 weeks) 
vs usual care 
 
I: n=21 
C: n=21 
executing functioning and 
motor function, verbal function 
and language skills, memory, 
self-reported cognitive 
function 
Kohli (2012)[40] 
 
USA 
Breast CA: 
Both arms: 100% 
 
Age:  
I: 54.0 (10.3) 
C: 56.35 (11.4) 
I: 100% chemo, 82% RT 
C: 100% chemo, 85% RT 
>30 days post chemo Modafinil 200 mg daily vs placebo for 4 weeks 
 
I: n=34 
C: n=34 
Orientation and attention, 
memory 
Short-term 
Lower (2009)[41] 
 
USA 
Breast CA: 
I: 78%  
C: 73%  
 
Age:  
I: 52.5 (10.2) 
C: 53.2 (8.4) 
I: 100% chemo 
C: 100% chemo 
Mean (SD): 115.3 
(106.5) weeks 
D-methylphenidate vs placebo for 8 weeks; 
dose modifications were allowed; max 50 
mg/day 
 
I: n=76 
C: n=78  
Orientation and attention 
 
Short-term 
Mar Fan 
(2008)[42] 
 
Canada 
Breast CA: 
Both arms: 100% 
 
Age: 
I: Median=50, 
Range= 36-72 
C: Median=51, 
Range= 37-74 
 
Both arms: 
100% Chemo 
 
Both arms: 
AC: 100% 
Cy: 96.5% 
5FU: 33.3% 
Taxane: 31.6% 
I: Median (range): 84 
(23-141) days post 
chemo 
 
C: Median (range): 85 
(26-131) days post 
chemo 
D-methylphenidate (titration: 5 to 10 mg twice 
daily) vs placebo until final cycle of chemo 
 
I: n=28 
C: n=29 
Memory Short-term 
Miki (2014)[43] 
 
Japan 
Breast CA: 
I: 55.3% 
C: 55.0% 
 
Age: 
I: 72.97 (4.57) 
C: 75.45 (6.57) 
 
I: 81.6% Surgery 
23.7% Chemo 
68.4% HT 
68.4% RT 
 
C: 72.5% Surgery 
27.5% Chemo 
80.0% HT 
4.00% RT 
 
Not stated 4-week Speed-feedback therapy with a bicycle 
ergometer vs usual care  
 
I: n=38 
C: n=40 
Executing function and motor 
function 
 
Short-term 
Milbury Breast CA: I: 100% chemo 6-60 months post Tibetan sound meditation (2x weekly sessions Orientation and attention, Short-term 
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Abbreviations: 5-FU: 5-Fluorouracil; AC: Anthracycline and cyclophosphamide; C: Control; CBT: Cognitive behavioral therapy; Cy: Cyclophosphamide; Chemo: Chemotherapy; FAC: 5-
Fluorouracil, anthracycline and cyclophosphamide; HT: Hormonal therapy, I: Intervention, RT: Radiation therapy. Tam: Tamoxifen. Measurement time points: short term: less than 3 months; 
medium term: 3-6 months; long term: beyond 6 months. 
(2014)[44] 
 
USA 
Both arms: 100% 
 
Age: 
I: 53.0 (6.6) 
C: 54.1 (8.6) 
73.9% RT 
87% Surgery 
 
C: 100% chemo 
79.2% RT 
100% Surgery 
chemo for 6 weeks) vs waitlist control  
 
I: n=18 
C: n=24 
Memory, verbal functions and 
language skills, self-reported 
cognitive function 
 
O’Shaughnessy 
(2005)[45] 
 
USA 
Breast CA: 
Both arms: 100% 
 
Age: 
I: 53.3 (9.7) 
C: 54.3 (12) 
Both arms: 
100% chemo 
 
Both arms: 
Doxorubicin/eprubicin:100%  
Cy: 96.8% 
5-FU: 11.7% 
Taxane: 24.5% 
Undergoing chemo 40,000 U epoetin alfa subcutaneous weekly vs 
placebo (started on D1 of cycle 1 of 4 cycles of 
chemo, and continued for a maximum of 12 
weeks). 
 
I: n=47 
C: n=47 
Executive function and motor 
function, self-reported 
cognitive function 
Short-term, 
long-term 
Von Ah 
(2012)[46] 
 
USA 
 
Breast CA: 
All three arms: 
100% 
 
Age: 
I1: 55.19 (7.58) 
I2: 56.93 (7.83) 
C: 57.21 (9.8) 
All three arms: 
100% chemo 
1 year post chemo Memory training (Advanced Cognitive 
Training for Independent and Vital Elderly 
(ACTIVE) program (10 sessions for 6-8 
weeks) vs speed of processing training (Posit 
Science®) (10 sessions for 6-8 weeks) vs 
waitlist group 
 
I1: n=29 
I2: n=30 
C: n=29 
Memory, self-reported 
cognitive function 
 
Short-term 
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Table 2. Risk of bias (ROB) table for included studies (n=13) 
 
Study Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
of bias 
Level of risk 
Barton (2013)[34] + 0 + + - + + H 
Culos-Reed (2006)[35] 0 0 0 - - - + H 
Dolbeault (2009)[36] + 0 - - - + + H 
Escalante (2014)[37] 0 0 + + 0 - + H 
Ferguson (2012)[38] + + + + + - + H 
Kesler (2013)[39] + 0 - 0 + + + H 
Kohli (2012)[40] + 0 + + + + - H 
Lower (2009)[41] + 0 + + + + + U 
Mar Fan (2008)[42] 0 0 + + + + + U 
Miki (2014)[43] + 0 - + + + + H 
Milbury (2014)[44] + 0 - 0 0 + + H 
O'Shaughnessy (2005)[45] + 0 + + - + + H 
Von Ah (2012)[46] + 0 - - + + + H 
0 represents an unclear ROB, - represents a high ROB, and + represents a low ROB. Abbreviations: H, high ROB (-) for one or more domains; L, low ROB (+) for all domains; U, 
unclear ROB for one or more domains. 
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Table 3. Pharmacologic interventions and outcomes (n=6) 
Categories Intervention Tool Domains 
examined 
Assessment time 
point 
Effect size Conclusion 
Psychostimulants 
Dexmethylphenidate[
41] 
Modified Swanson, Nelson and Pelham 
Attention Deficit/Hyperactivity Scale 
(SNAP) 
Orientation and 
attention 
Short-term MD=0.30 (95% CI, -2.19 to 
2.79) 
Negative 
Dexmethylphenidate[
42] 
Hopkins Verbal Learning Test-Revised 
(HVLT-R) 
Memory Medium-term RR=1.20 (95% CI, 0.72-
2.00) 
Negative 
Methylphenidate[37] Digit Span Orientation and attention 
Short-term Data not reported Inconclusive 
Modafinil[40] 
Cognitive Drug Research Computerized 
Assessment System# (Power of Attention) 
Orientation and 
attention 
Short-term MD=-27.64 (95% CI, -89.66 
to 34.38) 
Negative 
Cognitive Drug Research Computerized 
Assessment System# (Continuity of 
Attention) 
Orientation and 
attention 
Short-term MD=0.65 (95% CI: -0.65 to 
1.95) 
Negative 
Cognitive Drug Research Computerized 
Assessment System# (Episodic Secondary 
Memory) 
Memory Short-term MD=-4.52 (95% CI, -29.84 
to 20.80) 
Negative 
Cognitive Drug Research Computerized 
Assessment System# (Working Memory) 
Orientation and 
attention 
Short-term MD=0.12 (95% CI, -0.06 to 
0.30) 
 
Negative 
Cognitive Drug Research Computerized 
Assessment System# (Speed of Memory) 
Orientation and 
attention 
Short-term MD=-103.46 (95% CI,  
-567.03 to 360.10) 
Negative 
Erythropoietic 
stimulating agent Epoetin alfa[45] 
Executive Clock Drawing Task 1 (CLOX1) Executive 
function and 
motor function 
Short-term MD=0.10 (95% CI, -0.93 to 
1.13) 
Negative 
Executive Clock Drawing Task 1 (CLOX1) Executive 
function and 
motor function 
Long-term MD=-0.80 (95% CI, -1.83 to 
0.23) 
Negative 
The Executive Interview (EXIT-25) Self-reported 
cognitive 
function 
Short-term MD=-1.60 (95% CI, -2.81 to 
-0.39)* 
Positive 
The Executive Interview (EXIT-25) Self-reported 
cognitive 
function 
Long-term MD=-0.10 (95% CI, -1.35 to 
1.15) 
Negative 
Complementary 
alternative Gingko biloba[34] 
Trail Making Test-A Orientation and 
attention 
Short-term, 
medium-term, long-
Data not extractable Inconclusive 
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*p<0.05; #These subtest names do not appear in the original paper–they are derivative measures of a factor analysis. Positive represents ‘favors intervention’ and Negative represents 
‘does not favor intervention’. Measurement time points: short-term: less than 3 months; medium-term: 3-6 months; long-term: beyond 6 months. 
  
medicine term 
Trail Making Test-B Orientation and 
attention 
Short-term, 
medium-term, long-
term 
Data not extractable Inconclusive 
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Table 4. Non-pharmacologic interventions and outcomes (n=7) 
Categories Intervention Tool Domains examined Assessment 
time point 
Effect size Conclusion 
Cognitive 
training 
Computerized cognitive 
training[39] 
Wisconsin Card Sorting Test Executive function and 
motor function 
Short-term MD=3.00 (95% CI, -1.49 to 
7.49) 
Negative 
Delis-Kaplan (letter fluency) Verbal function and 
language skills 
Short-term MD=2.00 (95% CI, 0.78 to 
3.22)* 
Positive 
Digit Span Orientation and attention Short-term MD=0.90 (95% CI, -3.17 to 
1.17) 
Negative 
Symbol Search Orientation and attention Short-term MD=2.00 (95% CI, 0.16 to 
3.84)* 
Positive 
Hopkins Verbal Learning Test-
Revised (HVLT-R) 
Memory Short-term MD=1.00 (95% CI, -5.95 to 
3.95) 
Negative 
BRIEF GEC Self-reported cognitive 
function 
Short-term MD=-2.00 (95% CI, -10.37 
to 6.37) 
Negative 
BRIEF GEC (plan and organize) Self-reported cognitive 
function 
Short-term MD=-5.00 (95% CI -13.30 
to 3.30) 
Negative 
BRIEF GEC (task monitor) Self-reported cognitive 
function 
Short-term MD=-4.00 (95% CI, -10.75 
to 2.75) 
Negative 
Cognitive-behavioral 
therapy[38] 
Trail Making Test-B Orientation and attention Short-term MD=3.22 (95% CI, -7.9 to 
14.34) 
Negative 
Color Word Trail (D-KEFS subset) Executive function and 
motor function 
Short-term 
 
MD=-0.73 (95% CI, -6.44 to 
4.98) 
Negative 
Color Word Switching Trail (D-
KEFS subset) 
Executive function and 
motor function 
Short-term 
 
MD=0.53 (95% CI, -6.81 to 
7.87) 
Negative 
Digit Symbol-Coding (subtest of 
Wechsler Adult Intelligence Scale) 
Orientation and attention Short-term 
 
MD=1.09 (95% CI, -0.75 to 
2.93) 
Negative 
California Verbal Learning Test 
(CVLT) II 
Memory Short-term 
 
MD=4.26 (95% CI, -2.32 to 
10.84) 
Negative 
MASQ scores Self-reported cognitive 
function 
Short-term MD=4.02 (95% CI, -8.83 to 
16.87) 
Negative 
Memory training[46] 
FACT-Cog Self-reported cognitive 
function 
Short-term MD=9.85 (95% CI, 1.67 to 
18.03)* 
Positive 
Composite score: Rey Auditory 
Verbal Learning Test (AVLT) (sum 
recall, short delay and recognition 
Memory Short-term 
 
MD=0.31 (95% CI 0.04 to 
0.58)* 
Positive 
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score and  Rivermead Behavioral 
Paragraph Recall Test (immediate 
recall score) 
Composite score: Rey Auditory 
Verbal Learning Test (AVLT) (long 
term delay score)  and  Rivermead 
Behavioral Paragraph Recall Test 
(long term delay score)  
Memory Short-term MD=0.46 (95% CI, 0.12 to 
0.80)* 
Positive 
Speed of processing 
training[46] 
FACT-Cog Self-reported cognitive 
function 
Short-term MD=6.66 (95% CI, -1.43 to 
14.75) 
Negative 
Composite score: Rey Auditory 
Verbal Learning Test (AVLT) (sum 
recall, short delay and recognition 
score and  Rivermead Behavioral 
Paragraph Recall Test (immediate 
recall score) 
Memory Short-term 
 
MD=0.43 (95% CI, 0.16 to 
0.70)* 
Positive 
Composite score: Rey Auditory 
Verbal Learning Test (AVLT) (long 
term delay score)  and  Rivermead 
Behavioral Paragraph Recall Test 
(long term delay score)  
Memory Short-term MD=0.47 (95% CI, 0.13 to 
0.81)* 
Positive 
Psycho-education[36] EORTC-CF Self-reported cognitive function 
Short-term MD=-0.16 (95% CI, -0.38 to 
0.06) 
Negative 
Tibetan sound[44] 
Rey Auditory Verbal Learning Test 
(AVLT) 
Memory Short-term Data not extractable Inconclusive 
Digit Span Orientation and attention Short-term MD=0.43 (95% CI, -0.17 to 
1.03) 
Negative 
Digit Symbol-Coding (subtest of 
Wechsler Adult Intelligence Scale) 
Orientation and attention Short-term 
 
MD=0.46 (95% CI, -0.14 to 
1.06) 
Negative 
Controlled Oral Word Association 
Test 
Verbal function and 
language skills 
Short-term 
 
MD=0.00 (95% CI, -0.66 to 
0.66) 
Negative 
FACT-Cog (Impairment) Self-reported cognitive 
function 
Short-term MD=3.70 (95% CI, -8.20 to 
15.60) 
Negative 
FACT-Cog (Ability) Self-reported cognitive 
function 
Short-term MD=1.40 (95% CI, -3.06 to 
5.86) 
Negative 
FACT-Cog (Other Comment) Self-reported cognitive 
function 
Short-term MD=0.40 (95% CI, -1.57 to 
2.37) 
Negative 
FACT-Cog (Impact) Self-reported cognitive Short-term MD=0.10 (95% CI, -4.28 to Negative 
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*p<0.05; Positive represents ‘favors intervention’ and Negative represents ‘does not favor intervention’. Abbreviations: BRIEF GEC: Behavior Rating Inventory of Executive Function 
Global Executive Composite; EORTC-CF: European Organisation for Research and Treatment of Cancer-Cognitive functioning subscale; FACT-Cog: Functional Assessment of 
Cancer Therapy-Cognitive Function; GEC: Global Executive Composite; MASQ: Multiple Abilities Self-Report Questionnaire. Measurement time point: short-term: less than 3 
months. 
function 4.48) 
Exercise 
Speed-feedback therapy 
with a bicycle 
ergometer[43] 
Frontal Assessment Battery Executive function and 
motor function 
Short-term MD=1.66 (95% CI, 0.84 to 
2.48)* 
Positive 
Yoga[35] 
Symptoms of Stress Inventory 
(SOSI) Cognition Subscale 
Self-reported cognitive 
function 
Short-term MD=-1.67 (95% CI, -3.66 to 
0.32) 
Negative 
Profile of Moods Scale (POMS) 
Concentration Subscale 
Self-reported cognitive 
function 
Short-term MD=-2.50 (95% CI, -4.56 to 
-0.44)* 
Positive 
